Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.

Who are the leading players in the Evkeeza market? Key players in the Evkeeza market include the notable Regeneron Pharmaceuticals Inc., contributing significantly to the market growth.

The upcoming report from Regeneron (REGN) is expected to reveal ... Analysts forecast 'Revenues- Evkeeza- US' to reach $45.64 million. The estimate points to a change of +90.2% from the year ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...